Borg N, Ståhle L
Department of Clinical Pharmacology, Huddinge Hospital, SE-14186, Huddinge, Sweden.
Antimicrob Agents Chemother. 1998 Sep;42(9):2174-7. doi: 10.1128/AAC.42.9.2174.
Microdialysis was applied to sample the unbound drug concentration in the extracellular fluid in brain and muscle of rats given zalcitabine (2',3'-dideoxycytidine; n = 4) or BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine; n = 4) (50 mg/kg of body weight given subcutaneously). Zalcitabine and BEA005 were analyzed by high-pressure liquid chromatography with UV detection. The maximum concentration of zalcitabine in the dialysate (Cmax) was 31.4 +/- 5. 1 microM (mean +/- standard error of the mean) for the brain and 238. 3 +/- 48.1 microM for muscle. The time to Cmax was found to be from 30 to 45 min for the brain and from 15 to 30 min for muscle. Zalcitabine was eliminated from the brain and muscle with half-lives 1.28 +/- 0.64 and 0.85 +/- 0.13 h, respectively. The ratio of the area under the concentration-time curve (AUC) (from 0 to 180 min) for the brain and the AUC for muscle (AUC ratio) was 0.191 +/- 0.037. The concentrations of BEA005 attained in the brain and muscle were lower than those of zalcitabine, with Cmaxs of 5.7 +/- 1.4 microM in the brain and 61.3 +/- 12.0 microM in the muscle. The peak concentration in the brain was attained 50 to 70 min after injection, and that in muscle was achieved 30 to 50 min after injection. The half-lives of BEA005 in the brain and muscle were 5.51 +/- 1.45 and 0.64 +/- 0.06 h, respectively. The AUC ratio (from 0 to 180 min) between brain and muscle was 0.162 +/- 0.026. The log octanol/water partition coefficients were found to be -1.19 +/- 0.04 and -1.47 +/- 0.01 for zalcitabine and BEA005, respectively. The degrees of plasma protein binding of zalcitabine (11% +/- 4%) and BEA005 (18% +/- 2%) were measured by microdialysis in vitro. The differences between zalcitabine and BEA005 with respect to the AUC ratio (P = 0.481), half-life in muscle (P = 0.279), and level of protein binding (P = 0.174) were not statistically significant. The differences were statistically significant in the case of the half-life in the brain (P = 0.032), clearance (P = 0.046), volume of distribution (P = 0.027) in muscle, and octanol/water partition coefficient (P = 0.019).
采用微透析技术对皮下注射扎西他滨(2',3'-双脱氧胞苷;n = 4)或BEA005(2',3'-双脱氧-3'-羟甲基胞苷;n = 4)(50mg/kg体重)的大鼠脑和肌肉细胞外液中的游离药物浓度进行采样。扎西他滨和BEA005采用高压液相色谱-紫外检测法进行分析。扎西他滨在透析液中的最大浓度(Cmax)在脑中为31.4±5.1μM(平均值±平均标准误差),在肌肉中为238.3±48.1μM。达到Cmax的时间在脑中为30至45分钟,在肌肉中为15至30分钟。扎西他滨在脑和肌肉中的消除半衰期分别为1.28±0.64小时和0.85±0.13小时。脑浓度-时间曲线下面积(AUC)(0至180分钟)与肌肉AUC的比值(AUC比值)为0.191±0.037。BEA005在脑和肌肉中达到的浓度低于扎西他滨,脑中Cmax为5.7±1.4μM,肌肉中为61.3±12.0μM。脑内峰值浓度在注射后50至70分钟达到,肌肉中在注射后30至50分钟达到。BEA005在脑和肌肉中的半衰期分别为5.51±1.45小时和0.64±0.06小时。脑和肌肉之间的AUC比值(0至180分钟)为0.162±0.026。扎西他滨和BEA005的正辛醇/水分配系数分别为-1.19±0.04和-1.47±0.01。采用体外微透析法测定扎西他滨(11%±4%)和BEA005(18%±2%)的血浆蛋白结合率。扎西他滨和BEA005在AUC比值(P = 0.481)、肌肉半衰期(P = 0.279)和蛋白结合水平(P = 0.174)方面的差异无统计学意义。在脑半衰期(P = 0.032)、肌肉清除率(P = 0.046)、分布容积(P = 0.027)和正辛醇/水分配系数(P = 0.019)方面差异有统计学意义。